Is availability of anti-EGFR therapy for the colorectal adenocarcinomas showing fascin expression limited?
Colorectal adenocarcinoma (CRC) is a major cause of death. Fascin expression in CRCs was proved to be related with higher metastatic rates and poor prognosis, while metastatic patients with only wild type K-RAS gene are the candidates of recent molecularly targeted anti-epidermal growth factor recep...
Gespeichert in:
| Veröffentlicht in: | Targeted oncology 2014-06, Vol.9 (2), p.171-175 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 175 |
|---|---|
| container_issue | 2 |
| container_start_page | 171 |
| container_title | Targeted oncology |
| container_volume | 9 |
| creator | KOCER, Nazim Emrah KAYASELCUK, Fazilet |
| description | Colorectal adenocarcinoma (CRC) is a major cause of death. Fascin expression in CRCs was proved to be related with higher metastatic rates and poor prognosis, while metastatic patients with only wild type K-RAS gene are the candidates of recent molecularly targeted anti-epidermal growth factor receptor (EGFR) therapies. This study is designed to investigate the correlation between the fascin expression status and the K-RAS mutational status of CRCs in order to assess the availability rate of anti-EGFR therapies for patients with fascin-expressing CRCs. Immunohistochemical expression of fascin and mutational status of K-RAS were investigated in the archival materials of randomly selected 50 metastatic colorectal carcinoma patients. Strength of fascin expression and tumor percentage stained with fascin were scored semi quantitatively. c.34 > C (p.G12R), c.35 g > C (p.G12C), c.34G > A (p.G12S), c.35G > A (p.G12D), c.35G > T (p.G12V), c.35G > C (p.G12A), and c.38G > A (p.G13.D) mutations in K-RAS gene were studied by using RT-PCR. In immunohistochemical evaluation, 32 of the 50 cases stained positive with fascin, while 21 were positive for K-RAS mutations in codon 12 (10 patients) or in codon 13 (3 patients). The correlation between the positivity of fascin and the presence of K-RAS mutations, the strength of fascin staining and the presence of K-RAS mutations, and the tumor cell percentage stained with fascin and the presence of K-RAS mutations were found statistically significant. The results of this study suggest that patients with fascin-expressing CRCs have a greater tendency to carry an activating K-RAS mutation which will prevent them from taking targeted anti-EGFR therapies. Larger series are needed to confirm these results. |
| doi_str_mv | 10.1007/s11523-013-0275-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1534466025</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1534466025</sourcerecordid><originalsourceid>FETCH-LOGICAL-c402t-99d349b415d0341dd9cecba3bce829b812a0c7783c5fbadff4ad5c6aa9d314063</originalsourceid><addsrcrecordid>eNp1kV1rFDEUhoNYbK3-AG8kIAVvpuZ7Zq5ESlsLBUEUvAtn8tFmySRrMmvdf2-W3aoIXoQckuc95-W8CL2i5JwS0r-rlErGO0LbYb3shifohPa96pgi354-1nJUx-h5rStCRM8keYaOGZfDIKg8QaubiuEHhAhTiGHZ4uwxpCV0l9dXn_Fy7wqst9jnsquxyTEXZxaIGKxL2UAxIeUZKq73-SGkO-yhtifsfq6LqzXkhGOYw-Ls-xfoyEOs7uXhPkVfry6_XHzsbj9d31x8uO2MIGzpxtFyMU7NnSVcUGtH48wEfDJuYOM0UAbE9P3AjfQTWO8FWGkUQNNRQRQ_RW_3fdclf9-4uug5VONihOTypmoquRBKESYb-uYfdJU3JTV3O4qPTHE1NoruKVNyrcV5vS5hhrLVlOhdEHofhG5B6F0Qemia14fOm2l29rficfMNODsAbWEQfYFkQv3DDVL0ktLGsT1X21e6c-Uvi_-d_gt4AaEz</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1533926369</pqid></control><display><type>article</type><title>Is availability of anti-EGFR therapy for the colorectal adenocarcinomas showing fascin expression limited?</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>KOCER, Nazim Emrah ; KAYASELCUK, Fazilet</creator><creatorcontrib>KOCER, Nazim Emrah ; KAYASELCUK, Fazilet</creatorcontrib><description>Colorectal adenocarcinoma (CRC) is a major cause of death. Fascin expression in CRCs was proved to be related with higher metastatic rates and poor prognosis, while metastatic patients with only wild type K-RAS gene are the candidates of recent molecularly targeted anti-epidermal growth factor receptor (EGFR) therapies. This study is designed to investigate the correlation between the fascin expression status and the K-RAS mutational status of CRCs in order to assess the availability rate of anti-EGFR therapies for patients with fascin-expressing CRCs. Immunohistochemical expression of fascin and mutational status of K-RAS were investigated in the archival materials of randomly selected 50 metastatic colorectal carcinoma patients. Strength of fascin expression and tumor percentage stained with fascin were scored semi quantitatively. c.34 > C (p.G12R), c.35 g > C (p.G12C), c.34G > A (p.G12S), c.35G > A (p.G12D), c.35G > T (p.G12V), c.35G > C (p.G12A), and c.38G > A (p.G13.D) mutations in K-RAS gene were studied by using RT-PCR. In immunohistochemical evaluation, 32 of the 50 cases stained positive with fascin, while 21 were positive for K-RAS mutations in codon 12 (10 patients) or in codon 13 (3 patients). The correlation between the positivity of fascin and the presence of K-RAS mutations, the strength of fascin staining and the presence of K-RAS mutations, and the tumor cell percentage stained with fascin and the presence of K-RAS mutations were found statistically significant. The results of this study suggest that patients with fascin-expressing CRCs have a greater tendency to carry an activating K-RAS mutation which will prevent them from taking targeted anti-EGFR therapies. Larger series are needed to confirm these results.</description><identifier>ISSN: 1776-2596</identifier><identifier>EISSN: 1776-260X</identifier><identifier>DOI: 10.1007/s11523-013-0275-8</identifier><identifier>PMID: 23588415</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - genetics ; Adenocarcinoma - metabolism ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized - therapeutic use ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Biomedicine ; Carrier Proteins - biosynthesis ; Cetuximab ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - genetics ; Colorectal Neoplasms - metabolism ; DNA Mutational Analysis ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Immunohistochemistry ; Male ; Medical sciences ; Medicine ; Medicine & Public Health ; Microfilament Proteins - biosynthesis ; Middle Aged ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; Oncology ; Original Research ; Proto-Oncogene Proteins - genetics ; Proto-Oncogene Proteins p21(ras) ; ras Proteins - genetics ; Receptor, Epidermal Growth Factor - antagonists & inhibitors ; Reverse Transcriptase Polymerase Chain Reaction ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Tumors ; Young Adult</subject><ispartof>Targeted oncology, 2014-06, Vol.9 (2), p.171-175</ispartof><rights>Springer-Verlag France 2013</rights><rights>2015 INIST-CNRS</rights><rights>Springer International Publishing Switzerland 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c402t-99d349b415d0341dd9cecba3bce829b812a0c7783c5fbadff4ad5c6aa9d314063</citedby><cites>FETCH-LOGICAL-c402t-99d349b415d0341dd9cecba3bce829b812a0c7783c5fbadff4ad5c6aa9d314063</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11523-013-0275-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11523-013-0275-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28547511$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23588415$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KOCER, Nazim Emrah</creatorcontrib><creatorcontrib>KAYASELCUK, Fazilet</creatorcontrib><title>Is availability of anti-EGFR therapy for the colorectal adenocarcinomas showing fascin expression limited?</title><title>Targeted oncology</title><addtitle>Targ Oncol</addtitle><addtitle>Target Oncol</addtitle><description>Colorectal adenocarcinoma (CRC) is a major cause of death. Fascin expression in CRCs was proved to be related with higher metastatic rates and poor prognosis, while metastatic patients with only wild type K-RAS gene are the candidates of recent molecularly targeted anti-epidermal growth factor receptor (EGFR) therapies. This study is designed to investigate the correlation between the fascin expression status and the K-RAS mutational status of CRCs in order to assess the availability rate of anti-EGFR therapies for patients with fascin-expressing CRCs. Immunohistochemical expression of fascin and mutational status of K-RAS were investigated in the archival materials of randomly selected 50 metastatic colorectal carcinoma patients. Strength of fascin expression and tumor percentage stained with fascin were scored semi quantitatively. c.34 > C (p.G12R), c.35 g > C (p.G12C), c.34G > A (p.G12S), c.35G > A (p.G12D), c.35G > T (p.G12V), c.35G > C (p.G12A), and c.38G > A (p.G13.D) mutations in K-RAS gene were studied by using RT-PCR. In immunohistochemical evaluation, 32 of the 50 cases stained positive with fascin, while 21 were positive for K-RAS mutations in codon 12 (10 patients) or in codon 13 (3 patients). The correlation between the positivity of fascin and the presence of K-RAS mutations, the strength of fascin staining and the presence of K-RAS mutations, and the tumor cell percentage stained with fascin and the presence of K-RAS mutations were found statistically significant. The results of this study suggest that patients with fascin-expressing CRCs have a greater tendency to carry an activating K-RAS mutation which will prevent them from taking targeted anti-EGFR therapies. Larger series are needed to confirm these results.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - genetics</subject><subject>Adenocarcinoma - metabolism</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biomedicine</subject><subject>Carrier Proteins - biosynthesis</subject><subject>Cetuximab</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - genetics</subject><subject>Colorectal Neoplasms - metabolism</subject><subject>DNA Mutational Analysis</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Microfilament Proteins - biosynthesis</subject><subject>Middle Aged</subject><subject>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</subject><subject>Oncology</subject><subject>Original Research</subject><subject>Proto-Oncogene Proteins - genetics</subject><subject>Proto-Oncogene Proteins p21(ras)</subject><subject>ras Proteins - genetics</subject><subject>Receptor, Epidermal Growth Factor - antagonists & inhibitors</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Tumors</subject><subject>Young Adult</subject><issn>1776-2596</issn><issn>1776-260X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kV1rFDEUhoNYbK3-AG8kIAVvpuZ7Zq5ESlsLBUEUvAtn8tFmySRrMmvdf2-W3aoIXoQckuc95-W8CL2i5JwS0r-rlErGO0LbYb3shifohPa96pgi354-1nJUx-h5rStCRM8keYaOGZfDIKg8QaubiuEHhAhTiGHZ4uwxpCV0l9dXn_Fy7wqst9jnsquxyTEXZxaIGKxL2UAxIeUZKq73-SGkO-yhtifsfq6LqzXkhGOYw-Ls-xfoyEOs7uXhPkVfry6_XHzsbj9d31x8uO2MIGzpxtFyMU7NnSVcUGtH48wEfDJuYOM0UAbE9P3AjfQTWO8FWGkUQNNRQRQ_RW_3fdclf9-4uug5VONihOTypmoquRBKESYb-uYfdJU3JTV3O4qPTHE1NoruKVNyrcV5vS5hhrLVlOhdEHofhG5B6F0Qemia14fOm2l29rficfMNODsAbWEQfYFkQv3DDVL0ktLGsT1X21e6c-Uvi_-d_gt4AaEz</recordid><startdate>20140601</startdate><enddate>20140601</enddate><creator>KOCER, Nazim Emrah</creator><creator>KAYASELCUK, Fazilet</creator><general>Springer International Publishing</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20140601</creationdate><title>Is availability of anti-EGFR therapy for the colorectal adenocarcinomas showing fascin expression limited?</title><author>KOCER, Nazim Emrah ; KAYASELCUK, Fazilet</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c402t-99d349b415d0341dd9cecba3bce829b812a0c7783c5fbadff4ad5c6aa9d314063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - genetics</topic><topic>Adenocarcinoma - metabolism</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biomedicine</topic><topic>Carrier Proteins - biosynthesis</topic><topic>Cetuximab</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - genetics</topic><topic>Colorectal Neoplasms - metabolism</topic><topic>DNA Mutational Analysis</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Microfilament Proteins - biosynthesis</topic><topic>Middle Aged</topic><topic>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</topic><topic>Oncology</topic><topic>Original Research</topic><topic>Proto-Oncogene Proteins - genetics</topic><topic>Proto-Oncogene Proteins p21(ras)</topic><topic>ras Proteins - genetics</topic><topic>Receptor, Epidermal Growth Factor - antagonists & inhibitors</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Tumors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KOCER, Nazim Emrah</creatorcontrib><creatorcontrib>KAYASELCUK, Fazilet</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Targeted oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KOCER, Nazim Emrah</au><au>KAYASELCUK, Fazilet</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is availability of anti-EGFR therapy for the colorectal adenocarcinomas showing fascin expression limited?</atitle><jtitle>Targeted oncology</jtitle><stitle>Targ Oncol</stitle><addtitle>Target Oncol</addtitle><date>2014-06-01</date><risdate>2014</risdate><volume>9</volume><issue>2</issue><spage>171</spage><epage>175</epage><pages>171-175</pages><issn>1776-2596</issn><eissn>1776-260X</eissn><abstract>Colorectal adenocarcinoma (CRC) is a major cause of death. Fascin expression in CRCs was proved to be related with higher metastatic rates and poor prognosis, while metastatic patients with only wild type K-RAS gene are the candidates of recent molecularly targeted anti-epidermal growth factor receptor (EGFR) therapies. This study is designed to investigate the correlation between the fascin expression status and the K-RAS mutational status of CRCs in order to assess the availability rate of anti-EGFR therapies for patients with fascin-expressing CRCs. Immunohistochemical expression of fascin and mutational status of K-RAS were investigated in the archival materials of randomly selected 50 metastatic colorectal carcinoma patients. Strength of fascin expression and tumor percentage stained with fascin were scored semi quantitatively. c.34 > C (p.G12R), c.35 g > C (p.G12C), c.34G > A (p.G12S), c.35G > A (p.G12D), c.35G > T (p.G12V), c.35G > C (p.G12A), and c.38G > A (p.G13.D) mutations in K-RAS gene were studied by using RT-PCR. In immunohistochemical evaluation, 32 of the 50 cases stained positive with fascin, while 21 were positive for K-RAS mutations in codon 12 (10 patients) or in codon 13 (3 patients). The correlation between the positivity of fascin and the presence of K-RAS mutations, the strength of fascin staining and the presence of K-RAS mutations, and the tumor cell percentage stained with fascin and the presence of K-RAS mutations were found statistically significant. The results of this study suggest that patients with fascin-expressing CRCs have a greater tendency to carry an activating K-RAS mutation which will prevent them from taking targeted anti-EGFR therapies. Larger series are needed to confirm these results.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>23588415</pmid><doi>10.1007/s11523-013-0275-8</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1776-2596 |
| ispartof | Targeted oncology, 2014-06, Vol.9 (2), p.171-175 |
| issn | 1776-2596 1776-260X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1534466025 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adenocarcinoma - drug therapy Adenocarcinoma - genetics Adenocarcinoma - metabolism Adult Aged Aged, 80 and over Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents - therapeutic use Biological and medical sciences Biomedicine Carrier Proteins - biosynthesis Cetuximab Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Colorectal Neoplasms - metabolism DNA Mutational Analysis Female Gastroenterology. Liver. Pancreas. Abdomen Humans Immunohistochemistry Male Medical sciences Medicine Medicine & Public Health Microfilament Proteins - biosynthesis Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Oncology Original Research Proto-Oncogene Proteins - genetics Proto-Oncogene Proteins p21(ras) ras Proteins - genetics Receptor, Epidermal Growth Factor - antagonists & inhibitors Reverse Transcriptase Polymerase Chain Reaction Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Tumors Young Adult |
| title | Is availability of anti-EGFR therapy for the colorectal adenocarcinomas showing fascin expression limited? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T10%3A25%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%20availability%20of%20anti-EGFR%20therapy%20for%20the%20colorectal%20adenocarcinomas%20showing%20fascin%20expression%20limited?&rft.jtitle=Targeted%20oncology&rft.au=KOCER,%20Nazim%20Emrah&rft.date=2014-06-01&rft.volume=9&rft.issue=2&rft.spage=171&rft.epage=175&rft.pages=171-175&rft.issn=1776-2596&rft.eissn=1776-260X&rft_id=info:doi/10.1007/s11523-013-0275-8&rft_dat=%3Cproquest_cross%3E1534466025%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1533926369&rft_id=info:pmid/23588415&rfr_iscdi=true |